Angiostatin与肿瘤进展期的放射疗法相结合是安全的
WESTPORT, CT (Reuters Health) - The highly publicized angiogenesis inhibitor angiostatin is safe when combined with radiation therapy for advanced cancers, especially cancers of the head, neck, prostate, breast and lung, according to researchers from Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia.
Dr. Adam Dicker and colleagues were scheduled to report phase I study findings Wednesday at the Molecular Targets and Cancer Therapeutics meeting in Miami Beach, Florida. The American Association for Cancer Research, the National Cancer Institute, and the European Organization for Research and Treatment of Cancer are sponsors of the meeting.
"Another study found that angiostatin and radiation had a more than additive effect with angiostatin-enhancing radiotherapy," Dr. Dicker told Reuters Health. "So we wanted to discover if angiostatin was safe to give with radiotherapy," he said.
In the trial that included 15 patients, angiostatin was given five times a week before radiotherapy in a regimen lasting 5 to 7 weeks. "We found that angiostatin was safe when used with radiotherapy," Dr. Dicker said. The researchers did not see any additional toxicity other than what is normally expected with radiotherapy, and they are encouraged by the results, he noted. "We are continuing the trial at higher doses of angiostatin," Dr. Dicker added.
He noted that the results of this trial mirror those of another phase I trial at Thomas Jefferson University, done at the same time, in which patients who had failed other chemotherapy were given angiostatin. In that trial, he said, angiostatin was deemed safe with few side effects.
"We do not know how much of the patient response was due to radiation and how much was due to angiostatin," Dr. Dicker said. "The critical thing is that the drug alone is safe, and in combination with radiotherapy it is also safe. This is an important finding because it is thought that in clinical practice, these drugs will be used in combination with chemotherapy and radiotherapy."
Angiostatin is produced by Rockville, Maryland-based EntreMed, Inc.
-Westport Newsroom 203 319 2700, http://www.100md.com
Dr. Adam Dicker and colleagues were scheduled to report phase I study findings Wednesday at the Molecular Targets and Cancer Therapeutics meeting in Miami Beach, Florida. The American Association for Cancer Research, the National Cancer Institute, and the European Organization for Research and Treatment of Cancer are sponsors of the meeting.
"Another study found that angiostatin and radiation had a more than additive effect with angiostatin-enhancing radiotherapy," Dr. Dicker told Reuters Health. "So we wanted to discover if angiostatin was safe to give with radiotherapy," he said.
In the trial that included 15 patients, angiostatin was given five times a week before radiotherapy in a regimen lasting 5 to 7 weeks. "We found that angiostatin was safe when used with radiotherapy," Dr. Dicker said. The researchers did not see any additional toxicity other than what is normally expected with radiotherapy, and they are encouraged by the results, he noted. "We are continuing the trial at higher doses of angiostatin," Dr. Dicker added.
He noted that the results of this trial mirror those of another phase I trial at Thomas Jefferson University, done at the same time, in which patients who had failed other chemotherapy were given angiostatin. In that trial, he said, angiostatin was deemed safe with few side effects.
"We do not know how much of the patient response was due to radiation and how much was due to angiostatin," Dr. Dicker said. "The critical thing is that the drug alone is safe, and in combination with radiotherapy it is also safe. This is an important finding because it is thought that in clinical practice, these drugs will be used in combination with chemotherapy and radiotherapy."
Angiostatin is produced by Rockville, Maryland-based EntreMed, Inc.
-Westport Newsroom 203 319 2700, http://www.100md.com